{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:22:04Z","timestamp":1771654924479,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.02.027","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T10:06:54Z","timestamp":1470737214000},"page":"S86-S92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S","title":["Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia"],"prefix":"10.1016","volume":"16","author":[{"given":"Daniela","family":"Hoehn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana E.","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.02.027_bib1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2403071","article-title":"Imatinib inhibits the in\u00a0vitro development of the monocyte\/macrophage lineage from normal human bone marrow progenitors","volume":"17","author":"Dewar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.027_bib2","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib","volume":"105","author":"Dewar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.027_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1711.2004.01296.x","article-title":"Imatinib inhibits the functional capacity of cultured human monocytes","volume":"83","author":"Dewar","year":"2005","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.clml.2016.02.027_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/cc.4.7.1788","article-title":"Inhibition of c-fms by imatinib\u2014expanding the spectrum of treatment","volume":"4","author":"Dewar","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2016.02.027_bib5","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.027_bib6","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.027_bib7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.027_bib8","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.027_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.leukres.2013.02.005","article-title":"Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman","year":"2013","journal-title":"Leuk Res"},{"issue":"suppl 2","key":"10.1016\/j.clml.2016.02.027_bib10","first-page":"204","article-title":"Altered bone and mineral metabolism in\u00a0chronic phase CML patients treated with imatinib","volume":"92","author":"Jonsson","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.027_bib11","first-page":"281","article-title":"Dasatinib in chronic myeloid leukemia: a review","volume":"5","author":"Aguilera","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clml.2016.02.027_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14656566.2011.534780","volume":"12","author":"Doggrell","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2016.02.027_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.clml.2016.02.027_bib14","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.027_bib15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V\u2013independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.027_bib16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-06-0446","article-title":"Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells","volume":"6","author":"Nam","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2016.02.027_bib17","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2016.02.027_bib18","first-page":"734","article-title":"Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib","volume":"9","author":"Erba","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2016.02.027_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clinthera.2012.01.009","article-title":"Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"34","author":"Abbott","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2016.02.027_bib20","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.027_bib21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.027_bib22","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/leu.2008.237","article-title":"Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor","volume":"23","author":"Brownlow","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.027_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/leu.2008.356","article-title":"Therapeutic concentrations of dasatinib inhibit in\u00a0vitro osteoclastogenesis","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.027_bib24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2407-10-298","article-title":"The Src inhibitor dasatinib accelerates the differentiation of human bone marrow\u2013derived mesenchymal stromal cells into osteoblasts","volume":"10","author":"Id Boufker","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2016.02.027_bib25","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/onc.2010.73","article-title":"Src family kinase\/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts","volume":"29","author":"Lee","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2016.02.027_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0033-1343483","article-title":"TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model","volume":"225","author":"Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.clml.2016.02.027_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.taap.2011.04.019","article-title":"Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats","volume":"254","author":"Nurmio","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.clml.2016.02.027_bib28","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.clml.2016.02.027_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/CAD.0b013e328361feb0","article-title":"A\u00a0phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy","volume":"24","author":"Twardowski","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clml.2016.02.027_bib30","doi-asserted-by":"crossref","first-page":"e34914","DOI":"10.1371\/journal.pone.0034914","article-title":"Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects","volume":"7","author":"Garcia-Gomez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.02.027_bib31","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.humpath.2012.04.012","article-title":"Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia","volume":"43","author":"Hoehn","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2016.02.027_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/modpathol.3800026","article-title":"TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of BCR-ABL transcript type","volume":"17","author":"Luthra","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2016.02.027_bib33","first-page":"628","article-title":"Imatinib and altered bone and mineral metabolism\u2014the authors reply","volume":"355","author":"Berman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.027_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMc061565","article-title":"Imatinib and altered bone and mineral metabolism","volume":"355","author":"Tournis","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.027_bib35","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell\u2013dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clml.2016.02.027_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","article-title":"Effects of imatinib mesylate in osteoblastogenesis","volume":"37","author":"Tibullo","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2016.02.027_bib37","doi-asserted-by":"crossref","first-page":"R247","DOI":"10.1530\/ERC-12-0400","article-title":"Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies","volume":"21","author":"Aleman","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clml.2016.02.027_bib38","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":"The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in\u00a0vivo","volume":"25","author":"Vandyke","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clml.2016.02.027_bib39","first-page":"S441","article-title":"Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH (1\u201334)","volume":"15","author":"Fraher","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clml.2016.02.027_bib40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.0.1450681","article-title":"Serum measurement of osteoprotegerin\u2014clinical relevance and potential applications","volume":"145","author":"Hofbauer","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clml.2016.02.027_bib41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/ndt\/16.3.479","article-title":"Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis","volume":"16","author":"Sasaki","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clml.2016.02.027_bib42","first-page":"3162","article-title":"Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status","volume":"86","author":"Szulc","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clml.2016.02.027_bib43","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1002\/ibd.21714","article-title":"Circulating OPG levels are reduced following infliximab treatment and correlate with CRP levels: is serum OPG a potential marker of IBD disease activity?","volume":"17","author":"Galliera","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clml.2016.02.027_bib44","doi-asserted-by":"crossref","first-page":"w13050","DOI":"10.4414\/smw.2010.13050","article-title":"Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?","volume":"140","author":"Beyer","year":"2010","journal-title":"Swiss Med Wkly"},{"issue":"suppl 1","key":"10.1016\/j.clml.2016.02.027_bib45","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1136\/ard.2009.120196","article-title":"Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies","volume":"69","author":"Distler","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clml.2016.02.027_bib46","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2741\/2311","article-title":"Biology and clinical management of prostate cancer bone metastasis","volume":"12","author":"Ye","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.clml.2016.02.027_bib47","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with\u00a0metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:51Z","timestamp":1761870531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":47,"alternative-id":["S2152265016000823"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.027","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}